LATEST TRIALS

  • Solide Tumores
    A phase I/II , open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors
  • Multiple Diagnosis
    A phase I, open‐label, multi‐centre, multi‐dose, dose escalation study of LTX‐315 in patients with transdermally accessible tumours
  • Melanoma
    The Melanoma Goup Trial: TOL + vemurafenib followed by interferon + vemurafenib maintenance (BRAF-positive patients) or TOL followed by interferon maintenance (BRAF-negative patients)

NORDIC COOPERATION

Norway Norway Sweden Finland Aarhus Herlev Copenhagen